NQO1 and glioblastoma: In conclusion, targeting GSTP1 and NQO1 in general, and MNPC, specifically, are potentially promising therapeutic strategies for treating EGFRvIII-expressing GBM without demonstrable toxicities by taking advantage of a selective vulnerability that develops because of the generation of high levels of ROS species in these cells.